LENEXA, Kan.--(BUSINESS WIRE)--VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that preclinical in vivo screening of a series of synthetic analogs of calcitonin gene-related peptide (‘CGRP’), which naturally occurs in humans, retained the properties of CGRP at equal or greater potency. The Company will select one of these compounds to pursue for the treatment of heart failure, which is the nation’s most expensive disease. Heart failure affects five million Americans annually and is the number-one cause of death in persons over 65.
